These inhibitors covalently bind to CDK7 outside of the kinase domain and have shown excellent anti-tumor activity by exploiting the transcriptional vulnerability of oncogenes and cell cycle proteins in diverse cancer types [10–15]. The gene discussed is CDK7; the disease is neoplasm.